{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:20:08Z","timestamp":1793247608524,"version":"4.5.0"},"reference-count":83,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Unlike invasive aspergillosis, the prognosis and outcome of hematologic malignancy patients who develop invasive mucormycosis have not significantly improved over the past decade as a majority of patients who develop the infection still die 12 weeks after diagnosis. However, early recognition and treatment of invasive mucormycosis syndromes, as well as individualized approaches to treatment and secondary prophylaxis, could improve the odds of survival, even in the most persistently immunosuppressed patient receiving chemotherapy and\/or of stem cell transplantation. Herein, we describe the subtle clinical and radiographic clues that should alert the hematologist to the possibility of mucormycosis, and aggressive and timely treatment approaches that may limit the spread of infection before it becomes fatal. Hematology patients with this opportunistic infection require integrated care across several disciplines and frequently highly individualized and complex sequence of decision-making. We also offer perspectives for the use of 2 antifungals, amphotericin B products and posaconazole, with activity against Mucorales. The availability of posaconazole in an oral formulation that can be administered safely for prolonged periods makes it an attractive agent for long-term primary and secondary prophylaxis. However, serum drug concentration monitoring may be required to minimize breakthrough infection or relapsing mucormycosis associated with inadequate blood concentrations.<\/jats:p>","DOI":"10.1182\/blood-2011-03-316430","type":"journal-article","created":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T00:35:13Z","timestamp":1306542913000},"page":"1216-1224","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":328,"title":["How I treat mucormycosis"],"prefix":"10.1182","volume":"118","author":[{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas M. D. Anderson Cancer Center; and"},{"name":"University of Houston College of Pharmacy, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas M. D. Anderson Cancer Center; and"},{"name":"University of Houston College of Pharmacy, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111807055867000_B1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: pathophysiology, presentation, and management.","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"2019111807055867000_B2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases.","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019111807055867000_B3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.idc.2006.06.003","article-title":"Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management.","volume":"20","author":"Kontoyiannis","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"2019111807055867000_B4","first-page":"2973","article-title":"Agents of mucormycosis and related species.","volume-title":"Principles and Practice of Infectious Diseases","author":"Kontoyiannis","year":"2005","edition":"6th ed"},{"issue":"8","key":"2019111807055867000_B5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"issue":"9","key":"2019111807055867000_B6","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3201\/eid1509.090334","article-title":"Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.","volume":"15","author":"Bitar","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"2019111807055867000_B7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2019111807055867000_B8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2019111807055867000_B9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center.","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"22","key":"2019111807055867000_B10","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJM195705302562202","article-title":"Pulmonary mucormycosis in acute histiocytic leukemia.","volume":"256","author":"Stefanini","year":"1957","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807055867000_B11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10096-006-0107-1","article-title":"Zygomycosis: the re-emerging fungal infection.","volume":"25","author":"Chayakulkeeree","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2019111807055867000_B12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1469-0691.2009.02982.x","article-title":"Outbreaks of zygomycosis in hospitals.","volume":"15","author":"Antoniadou","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"2019111807055867000_B13","first-page":"986","article-title":"Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).","volume":"91","author":"Chamilos","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2019111807055867000_B14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236","article-title":"Zygomycetes in human disease.","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"2019111807055867000_B15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection","volume":"47","author":"Garcia-Vidal","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019111807055867000_B16","first-page":"409","article-title":"Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature.","volume":"17","author":"Gaziev","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111807055867000_B17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1701885","article-title":"Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of role of iron overload in pathogenesis.","volume":"24","author":"Maertens","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"2019111807055867000_B18","first-page":"1","article-title":"Breakthrough zygomycosis following empirical caspofungin treatment: report of two patients with leukemia and literature review.","author":"Sujobert","year":"2010","journal-title":"Open J Hematol"},{"issue":"5","key":"2019111807055867000_B19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2019111807055867000_B20","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents: pharmacokinetics, safety and efficacy.","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"issue":"50","key":"2019111807055867000_B21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2009.02988.x","article-title":"Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?","volume":"15","author":"Pongas","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"2019111807055867000_B22","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/652762","article-title":"Geoclimatic factors and invasive aspergillosis after allogeneic hematopoietic stem cell transplantation: new perspectives for patient management?","volume":"50","author":"Viscoli","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"24","key":"2019111807055867000_B23","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111807055867000_B24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer.","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2019111807055867000_B25","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1086\/587991","article-title":"Reversed halo sign in invasive pulmonary fungal infections.","volume":"46","author":"Wahba","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2019111807055867000_B26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1378\/chest.121.2.527","article-title":"Role of fine-needle aspirates of focal lung lesions in patients with hematologic malignancies.","volume":"121","author":"Wong","year":"2002","journal-title":"Chest"},{"issue":"2","key":"2019111807055867000_B27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.923","article-title":"CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions.","volume":"28","author":"Gupta","year":"2010","journal-title":"Hematol Oncol"},{"key":"2019111807055867000_B28","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.25905","article-title":"Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study.","author":"Sampsonas","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"2019111807055867000_B29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/bmt.2009.203","article-title":"Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation.","volume":"45","author":"Shannon","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111807055867000_B30","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1086\/521245","article-title":"The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients.","volume":"45","author":"Lass-Florl","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019111807055867000_B31","first-page":"105","volume-title":"Medically Important Fungi: A Guide to Identification","author":"Larone","year":"1995","edition":"3rd ed"},{"issue":"2","key":"2019111807055867000_B32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jinf.2009.06.002","article-title":"A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response.","volume":"59","author":"Ben-Ami","year":"2009","journal-title":"J Infect"},{"issue":"6","key":"2019111807055867000_B33","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1309\/EXBVYAUPENBM285Y","article-title":"Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologic examination.","volume":"119","author":"Tarrand","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2019111807055867000_B34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1309\/7KU5XWURYM0151YN","article-title":"Increased culture recovery of Zygomycetes under physiologic temperature conditions.","volume":"127","author":"Kontoyiannis","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2019111807055867000_B35","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/JCM.00036-09","article-title":"Spectrum of zygomycete species identified in clinically significant specimens in the United States.","volume":"47","author":"Alvarez","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"11","key":"2019111807055867000_B36","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/JCM.00917-08","article-title":"Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis.","volume":"46","author":"Kasai","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"6","key":"2019111807055867000_B37","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/JCM.02319-09","article-title":"Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation.","volume":"48","author":"Dannaoui","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2019111807055867000_B38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1128\/JCM.44.2.340-349.2006","article-title":"Molecular identification of zygomycetes from culture and experimentally infected tissues.","volume":"44","author":"Schwarz","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"4","key":"2019111807055867000_B39","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis.","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2019111807055867000_B40","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2019111807055867000_B41","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/599105","article-title":"Recent advances in the management of mucormycosis: from bench to bedside.","volume":"48","author":"Spellberg","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019111807055867000_B42","first-page":"2223","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications.","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2019111807055867000_B43","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2019111807055867000_B44","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Posaconazole: a broad-spectrum triazole antifungal agent.","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2019111807055867000_B45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1086\/587755","article-title":"The effect of gastric acid on the absorption of posaconazole.","volume":"46","author":"Jain","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2019111807055867000_B46","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"10","key":"2019111807055867000_B47","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2019111807055867000_B48","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.01222-09","article-title":"Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.","volume":"54","author":"Lewis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2019111807055867000_B49","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2009.04.007","article-title":"Fatal Rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature.","volume":"15","author":"Lekakis","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111807055867000_B50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1078155208094123","article-title":"Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up.","volume":"14","author":"Kishel","year":"2008","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"2019111807055867000_B51","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","article-title":"In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.","volume":"51","author":"Almyroudis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2019111807055867000_B52","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2019111807055867000_B53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis.","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111807055867000_B54","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2019111807055867000_B55","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2019111807055867000_B56","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1086\/587101","article-title":"When primary antifungal therapy fails.","volume":"46","author":"Nucci","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2019111807055867000_B57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications.","volume":"110","author":"Miceli","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"2019111807055867000_B58","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/archinte.159.12.1301","article-title":"Pulmonary mucormycosis: the last 30 years.","volume":"159","author":"Lee","year":"1999","journal-title":"Arch Intern Med"},{"issue":"2","key":"2019111807055867000_B59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000315675","article-title":"Lessons from a case of oromandibular mucormycosis treated with surgery and combination of amphotericin B lipid formulation plus caspofungin.","volume":"124","author":"Ojeda-Uribe","year":"2010","journal-title":"Acta Haematol"},{"issue":"4","key":"2019111807055867000_B60","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","article-title":"Pulmonary mucormycosis: results of medical and surgical therapy.","volume":"57","author":"Tedder","year":"1994","journal-title":"Ann Thorac Surg"},{"issue":"9398","key":"2019111807055867000_B61","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections.","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"2019111807055867000_B62","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis.","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"2019111807055867000_B63","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2337\/diacare.31.12.1109","article-title":"A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability.","volume":"31","author":"Artis","year":"1982","journal-title":"Diabetes"},{"issue":"5","key":"2019111807055867000_B64","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI116419","article-title":"Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies.","volume":"91","author":"Boelaert","year":"1993","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111807055867000_B65","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/QCO.0b013e3283165fd1","article-title":"Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.","volume":"21","author":"Ibrahim","year":"2008","journal-title":"Curr Opin Infect Dis"},{"issue":"7","key":"2019111807055867000_B66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis.","volume":"11","author":"John","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"2019111807055867000_B67","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.emc.2008.01.005","article-title":"Hyperbaric oxygen: applications in infectious disease.","volume":"26","author":"Kaide","year":"2008","journal-title":"Emerg Med Clin North Am"},{"issue":"2","key":"2019111807055867000_B68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1086\/317943","article-title":"Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases.","volume":"183","author":"Hubel","year":"2001","journal-title":"J Infect Dis"},{"issue":"8","key":"2019111807055867000_B69","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.inf.0000134314.65398.bf","article-title":"Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children.","volume":"23","author":"Abzug","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"2019111807055867000_B70","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1086\/340221","article-title":"Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases.","volume":"185","author":"Hubel","year":"2002","journal-title":"J Infect Dis"},{"issue":"7","key":"2019111807055867000_B71","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/428503","article-title":"Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes.","volume":"191","author":"Gil-Lamaignere","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"2019111807055867000_B72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13693780701639546","article-title":"The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections.","volume":"46","author":"Chamilos","year":"2008","journal-title":"Med Mycol"},{"issue":"11","key":"2019111807055867000_B73","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00277-005-1055-z","article-title":"Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia.","volume":"84","author":"Moussett","year":"2005","journal-title":"Ann Hematol"},{"issue":"l","key":"2019111807055867000_B74","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients.","volume":"66","author":"Pagano","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2019111807055867000_B75","first-page":"862","article-title":"Infections caused by filamentous fungi in patients with hematologic malignancies: a report of 391 cases by GIMEMA Infection Program.","volume":"86","author":"Pagano","year":"2001","journal-title":"Haematologica"},{"issue":"2","key":"2019111807055867000_B76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/CMR.00056-10","article-title":"Mucormycosis caused by unusual mucormycetes, non-rhizopus, -mucor, and -lichtheimia species.","volume":"24","author":"Gomes","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2019111807055867000_B77","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2010.256","article-title":"Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.","volume":"46","author":"Kontoyiannis","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111807055867000_B78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bmt.2009.262","article-title":"Safe living after hematopoietic cell transplantation.","volume":"44","author":"Yokoe","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111807055867000_B79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1011900630987","article-title":"Mycopathologia animal models of zygomycosis: Absidia, Rhizopus, Rhizomucor, and Cunninghamella.","volume":"152","author":"Kamei","year":"2001","journal-title":"Mycopathologia"},{"issue":"105","key":"2019111807055867000_B80","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1073\/pnas.0709578105","article-title":"Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.","volume":"8","author":"Chamilos","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111807055867000_B81","doi-asserted-by":"crossref","first-page":"e1000549","DOI":"10.1371\/journal.pgen.1000549","article-title":"Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication.","volume":"5","author":"Ma","year":"2009","journal-title":"PLoS Genet"},{"issue":"6","key":"2019111807055867000_B82","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1172\/JCI42164","article-title":"The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.","volume":"120","author":"Liu","year":"2010","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111807055867000_B83","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/589290","article-title":"Immunocompromised hosts: immunopharmacology of modern antifungals.","volume":"47","author":"Ben-Ami","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/5\/1216\/1347543\/zh803111001216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/5\/1216\/1347543\/zh803111001216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T06:13:34Z","timestamp":1712470414000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/5\/1216\/28983\/How-I-treat-mucormycosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,4]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,8,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-316430","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,4]]}}}